Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.33% $1.366
America/New_York / 24 apr 2024 @ 12:01
FUNDAMENTALS | |
---|---|
MarketCap: | 102.03 mill |
EPS: | -0.530 |
P/E: | -2.58 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 74.72 mill |
Avg Daily Volume: | 0.371 mill |
RATING 2024-04-23 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.58 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.44x |
Company: PE -2.58 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.163 - 1.525 ( +/- 13.47%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Gibney Anthony S | Buy | 93 290 | Common Stock |
2024-04-17 | Gibney Anthony S | Buy | 6 710 | Common Stock |
2024-04-15 | Gibney Anthony S | Buy | 45 000 | Stock Option (right to buy) |
2024-04-15 | Gibney Anthony S | Buy | 0 | |
2024-03-20 | Chong Ngai Hang Victor | Buy | 30 000 | Common Stock |
INSIDER POWER |
---|
66.33 |
Last 97 transactions |
Buy: 5 495 368 | Sell: 2 175 231 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.366 (-0.33% ) |
Volume | 0.125 mill |
Avg. Vol. | 0.371 mill |
% of Avg. Vol | 33.77 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.